OA11464A - Combination of active principles, in particular oftetrahydropyridins and acetylcholinesterase inhib iting agents, for treating senile dementia such asAlzheimer dementia. - Google Patents

Combination of active principles, in particular oftetrahydropyridins and acetylcholinesterase inhib iting agents, for treating senile dementia such asAlzheimer dementia. Download PDF

Info

Publication number
OA11464A
OA11464A OA1200000141A OA1200000141A OA11464A OA 11464 A OA11464 A OA 11464A OA 1200000141 A OA1200000141 A OA 1200000141A OA 1200000141 A OA1200000141 A OA 1200000141A OA 11464 A OA11464 A OA 11464A
Authority
OA
OAPI
Prior art keywords
tetrahydropyridine
ethyl
trifluoromethylphenyl
biphenylyl
alkyl
Prior art date
Application number
OA1200000141A
Other languages
English (en)
Inventor
Jean-Pierre Maffrand
Philippe Soubrie
Jean-Paul Terranova
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9714324A external-priority patent/FR2771006B1/fr
Priority claimed from FR9714322A external-priority patent/FR2771007B1/fr
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of OA11464A publication Critical patent/OA11464A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
OA1200000141A 1997-11-14 2000-05-12 Combination of active principles, in particular oftetrahydropyridins and acetylcholinesterase inhib iting agents, for treating senile dementia such asAlzheimer dementia. OA11464A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9714324A FR2771006B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer
FR9714322A FR2771007B1 (fr) 1997-11-14 1997-11-14 Association de principes actifs pour le traitement de la demence senile du type alzheimer

Publications (1)

Publication Number Publication Date
OA11464A true OA11464A (en) 2003-11-18

Family

ID=26233932

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200000141A OA11464A (en) 1997-11-14 2000-05-12 Combination of active principles, in particular oftetrahydropyridins and acetylcholinesterase inhib iting agents, for treating senile dementia such asAlzheimer dementia.

Country Status (27)

Country Link
EP (1) EP1030671A1 (fr)
JP (1) JP2001523642A (fr)
KR (1) KR100599350B1 (fr)
CN (1) CN1243540C (fr)
AU (1) AU743228B2 (fr)
BG (1) BG64819B1 (fr)
BR (1) BR9814035A (fr)
CA (1) CA2309966A1 (fr)
CO (1) CO4980891A1 (fr)
DZ (1) DZ2649A1 (fr)
EA (1) EA003255B1 (fr)
EE (1) EE04235B1 (fr)
HU (1) HUP0100098A3 (fr)
ID (1) ID24933A (fr)
IL (2) IL136122A0 (fr)
IS (1) IS5482A (fr)
MY (1) MY120461A (fr)
NO (1) NO20002450L (fr)
NZ (1) NZ504420A (fr)
OA (1) OA11464A (fr)
PL (1) PL194597B1 (fr)
SA (1) SA98190747B1 (fr)
SK (1) SK286040B6 (fr)
TR (1) TR200001262T2 (fr)
TW (1) TW585766B (fr)
UY (1) UY25247A1 (fr)
WO (1) WO1999025363A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE041842T2 (hu) 2002-06-14 2019-05-28 Toyama Chemical Co Ltd Gyógyászati készítmény agymûködés javítására
JP2005534710A (ja) * 2002-08-07 2005-11-17 ノバルティス アクチエンゲゼルシャフト Ａｐｏｅ遺伝子型を基準とした痴呆を処置するための方法
CN1520818A (zh) * 2003-02-09 2004-08-18 ɽ����Ҷ��Ȼҩ���о��������޹�˾ 治疗老年性痴呆的胆碱酯酶抑制剂药物组合物
MX2007007836A (es) 2004-12-27 2007-08-20 Eisai R&D Man Co Ltd Metodo para estabilizar un farmaco anti-demencia.
RU2692258C2 (ru) 2014-01-31 2019-06-24 Когнишн Терапьютикс, Инк. Композиции изоиндолина и способы лечения нейродегенеративного заболевания
DK3634394T3 (da) 2017-05-15 2026-03-02 Cognition Therapeutics Inc Sammensætninger til behandling af neurogenerative sygdomme
KR102224918B1 (ko) 2018-03-20 2021-03-09 (주)인벤티지랩 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법
WO2019182319A1 (fr) * 2018-03-20 2019-09-26 (주)인벤티지랩 Procédé de préparation de composition pharmaceutique de prévention ou de traitement de maladies associées au trouble cognitif, et composition pharmaceutique de prévention ou de traitement de maladies associées au trouble cognitif, préparée par le procédé de préparation
CN109265391B (zh) * 2018-11-13 2021-11-19 枣庄学院 联苯多取代1,2,5,6-四氢吡啶化合物及其合成方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
US5453428A (en) * 1991-02-14 1995-09-26 The Mount Sinai School Of Medicine Of The City Of New York Method and composition for the treatment of apathy-amotivation syndrome
ES2244968T3 (es) * 1995-03-06 2005-12-16 Interneuron Pharmaceuticals Incorporated Reduccion del volumen de infarto usando citocolina.
FR2736053B1 (fr) * 1995-06-28 1997-09-19 Sanofi Sa Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines

Also Published As

Publication number Publication date
CN1285742A (zh) 2001-02-28
EP1030671A1 (fr) 2000-08-30
DZ2649A1 (fr) 2004-12-28
BR9814035A (pt) 2000-09-26
TW585766B (en) 2004-05-01
CA2309966A1 (fr) 1999-05-27
BG64819B1 (bg) 2006-05-31
UY25247A1 (es) 2001-05-31
EE200000290A (et) 2001-06-15
AU1160999A (en) 1999-06-07
KR100599350B1 (ko) 2006-07-12
CO4980891A1 (es) 2000-11-27
NZ504420A (en) 2003-08-29
PL194597B1 (pl) 2007-06-29
SK286040B6 (sk) 2008-01-07
IL136122A (en) 2006-07-05
EA200000412A1 (ru) 2000-12-25
KR20010032099A (ko) 2001-04-16
NO20002450D0 (no) 2000-05-11
JP2001523642A (ja) 2001-11-27
EA003255B1 (ru) 2003-02-27
SA98190747B1 (ar) 2006-11-04
CN1243540C (zh) 2006-03-01
BG104428A (en) 2001-08-31
TR200001262T2 (tr) 2001-01-22
IS5482A (is) 2000-05-09
SK7112000A3 (en) 2000-10-09
EE04235B1 (et) 2004-02-16
HUP0100098A2 (hu) 2001-07-30
MY120461A (en) 2005-10-31
IL136122A0 (en) 2001-05-20
NO20002450L (no) 2000-07-14
PL340500A1 (en) 2001-02-12
WO1999025363A1 (fr) 1999-05-27
ID24933A (id) 2000-08-31
HUP0100098A3 (en) 2001-12-28
AU743228B2 (en) 2002-01-24

Similar Documents

Publication Publication Date Title
CA2282654C (fr) Utilisation d'inhibiteurs de la cholinesterase pour traiter l'hyperactivite avec deficit de l'attention
EP0216555B1 (fr) Utilisation de dérivés de la dioxopipéridine pour le traitement de l'anxiété, pour la réduction des niveaux de la sérotonine ou de l'acide 5-hydroxy-indoleacétique chroniquement anormalement élevés dans le cerveau, et pour le traitement des infections bact
JPH08225464A (ja) 嘔吐治療用ｎｋ−１受容体アンタゴニスト及び５ｈｔ３受容体アンタゴニスト
NZ547152A (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
CA2323618A1 (fr) Combinaison d'un agoniste inverse alpha 5 gaba-a et inhibiteur d'acetylcholinesterase
OA11464A (en) Combination of active principles, in particular oftetrahydropyridins and acetylcholinesterase inhib iting agents, for treating senile dementia such asAlzheimer dementia.
Stewart et al. The pharmacological characterisation of pilocarpine-induced purposeless chewing behaviour in the rat
US20030092737A1 (en) Combination of active ingredients for the treatment of senile dementia of the Alzheimer type
US4479956A (en) Analgesic compositions comprising propiram and methods of using same
HU197206B (en) Process for production of medical compounds decreasing blood-pressure
HU183119B (en) Process for producing analgesic and tone-delivering compositions containing quinazoline derivatives and benzothiadiazol derivatives
MXPA00004600A (en) Combination of active principles, in particular of tetrahydropyridins and acetylcholinesterase inhibiting agents, for treating senile dementia such as alzheimer dementia
CZ20001734A3 (cs) Farmaceutická kompozice a její použití
US5852044A (en) Use of NK1 receptor antagonists for preparing cardio-regulatory drugs
DE3736505A1 (de) Kombination von clacium antagonisten mit einem ace-hemmer
TH65396C3 (th) องค์ประกอบสำหรับให้ทางปากของ 8-คลอโร-6, 11-ไดไฮโดร-11-(4-ปิปเปอริดิลลิดีน)-5H-เบนโซ[5,6] ไซโคลเฮปตา[1,2-b] ไพริดีน
TH48162A3 (th) องค์ประกอบสำหรับให้ทางปากของ 8-คลอโร-6, 11-ไดไฮโดร-11-(4-ปิปเปอริดิลลิดีน)-5H-เบนโซ[5,6] ไซโคลเฮปตา[1,2-b] ไพริดีน
FR2771007A1 (fr) Association de principes actifs pour le traitement de la demence senile du type alzheimer
JPWO2001022997A1 (ja) 鎮痛薬
SI21062A2 (sl) Farmacevtski sestavki, ki obsegajo amlodipin maleat